ProBioGen will develop a biopharmaceutical cell line for high-level production of one of Affitech’s lead oncology candidates.
Under the terms of the agreement, ProBioGen will apply its cell-generation process for biopharmaceutical cell lines relying on the unique vectors and its pre-optimized CHO starter cell. This will be combined with an automated cloning process to identify and develop a high producer line, which should be particularly suitable for a fed-batch development process.
“Our unique approach in developing high producer cell lines combined with our royalty-free business model is very attractive to our customers and provides them with one of the crucial key features for a successful production process,” says Michael Schlenk, CEO at ProBioGen.
Commenting on the agreement, Martin Welschof, CEO of Affitech, remarks, "While several of our in-house discovered human antibodies are in various stages of preclinical development, in order to meet the demands of our ambitious development program for oncology antibody therapeutics, we have chosen a partner who offers us a high degree of flexibility and a compatible service-based development model.”